Clearside Biomedical, Inc.
CLSD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.61 | 0.00 | -4.21 |
| FCF Yield | -36.62% | -27.54% | -20.19% | -6.67% |
| EV / EBITDA | -4.21 | -3.75 | -1.85 | 236.63 |
| Quality | ||||
| ROIC | -139.48% | -88.94% | -63.93% | -1.62% |
| Gross Margin | 91.05% | 95.68% | 84.63% | 100.00% |
| Cash Conversion Ratio | 0.72 | 0.56 | 0.41 | -28.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.84% | -34.72% | -44.81% | 138.76% |
| Free Cash Flow Growth | -28.94% | -46.29% | -26.81% | 18.54% |
| Safety | ||||
| Net Debt / EBITDA | -1.33 | -0.61 | 0.44 | -53.72 |
| Interest Coverage | -2.95 | -2.65 | -9.07 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,445.70 | -2,259.57 | -1,878.68 | 123.42 |